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Background: Human immunodeficiency virus type 1 (HIV-1) Vif hijacks an E3 ligase to suppress natural APOBEC3
restriction factors, and core binding factor β (CBF-β) is required for this process. Although an extensive region of Vif
spanning most of its N-terminus is known to be critical for binding with CBF-β, involvement of the Vif C-terminus in
the interaction with CBF-β has not been fully investigated.
Results: Here, through immunoprecipitation analysis of Vif C-terminal truncated mutants of various lengths, we
identified that CBF-β binding requires not only certain amino acids (G126A, E134A, Y135A and G138A) in the HCCH
region but also the HCCH motif itself, which also affects the Vif-mediated suppression of APOBEC3G/APOBEC3F
(A3G/A3F). These mutants still maintained interactions with substrate A3G or A3F as well as other cellular factors
ElonginB/C (ELOB/C), indicating that their structures were not functionally affected. Moreover, by determining that the
BC box also is necessary for CBF-β interaction in vivo, we speculate that binding to ELOB/C induces conformational
changes in Vif, facilitating its interaction with CBF-β and consequent interaction with CUL5.
Conclusions: These results provide important information on the assembly of the Vif-CUL5-E3 ubiquitin ligase.
Identification of the new binding interface with CBF-β at the C-terminus of HIV-1 Vif also provides novel targets
for the development of HIV-1 inhibitors.
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Polynucleotide cytidine deaminases comprise a large fam-
ily of proteins, including AID, APOBEC1, APOBEC2,
APOBEC4 and seven APOBEC3 proteins (A3A, A3B,
A3C, A3DE, A3F, A3G, A3H). APOBEC3 proteins were
discovered to have antiviral or anti-retrotransposon activ-
ities of varying degrees [1-13]. To counteract these host
restriction factors, the HIV-1 Vif protein hijacks host
Cullin5 (CUL5), ElonginB/ElonginC (ELOB/C) and a
newly identified host factor CBF-β to form an E3 ubiquitin
ligase to induce APOBEC3 protein ubiquitination and
degradation [14-26].* Correspondence: xyu2@jhu.edu; zhangwenyan@jlu.edu.cn
†Equal contributors
1Institute of Virology and AIDS Research, First Hospital of Jilin University, No
519. East Minzhu Avenue, Changchun, Jilin Province, China
3Department of Molecular Microbiology and Immunology, Johns Hopkins
Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, USA
Full list of author information is available at the end of the article
© 2014 Wang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.HIV-1 Vif is a 23-kDa protein with 192 residues. Pre-
vious studies have identified multiple functional domains
in HIV-1 Vif (Figure 1A) [27,28]. In its C-terminus, a
virus-specific region, termed BC box, is required for
interaction with ELOB/C [29-32]. Furthermore, a highly
conserved H-X5-C-X17-18C3-5-H motif (HCCH motif )
upstream of the BC box, the CUL5 box downstream of
the BC box and an N-terminal motif are responsible for
CUL5 binding [32-40]. The N-terminal domain of Vif is
important for binding to its APOBEC3 substrate [41-47].
The Vif Y40RHHY44 motif is specific for A3G binding
(G box) [46], while D14RMR17 and T74GERxW79 both
are specific for A3F binding (F box) [41,46]. The com-




As a newly identified Vif regulator in 2011, CBF-β has
been shown to be critical for Vif-mediated degradation of
APOBEC3 family proteins [20-24,48,49]. CBF-β increasestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Effects of C-terminal truncations on HIV-1 Vif function. (A) Construction of C-terminal truncated Vif mutants with an N-terminal HA tag.
(B) Interactions of various truncated Vif mutants with cellular factors. HEK293T cells were transfected with VR1012 as a control vector or WT or truncated
Vif mutants as indicated. Cells were harvested 48 h later and subjected to immunoprecipitation analysis using the anti-HA antibody conjugated to
agarose beads. Co-precipitated proteins were analyzed by Western blotting against Vif-HA, CUL5, CBF-β and ELOB. (C) Effects of WT and truncated Vif
proteins on A3G degradation and virion packaging. HEK293T cells were co-transfected with NL4-3ΔVif and A3G along with VR1012 as a control vector
or WT or various truncated Vifs as indicated. A3G expression was assessed by Western blotting against A3G-HA, Vif-HA and tubulin as loading control.
A3G packaging was evaluated by Western blotting against A3G-HA and CAp24 after virus was purified from the supernatant of cell cultures. (D) Effects
of WT and truncated Vif proteins on antiviral activity of A3G. HIV-1 viruses were produced as described for panel C. Virus infectivity was assessed using
MAGI indicator cells, with the virus infectivity in the presence of WT Vif set to 100%. Error bars represent the standard deviation from triplicate wells.
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acts with this viral protein to control its binding to CUL5
[20,22,23]. CBF-β also increases Vif solubility when co-
expressed in vitro [23].
Recent studies suggested that the N-terminal amino
acids of Vif, including dispersed and conserved hydropho-
bic amino acids, are important for binding with CBF-β
[50-52]. However, whether the C-terminus of HIV-1 Vif is
also required for its interaction with CBF-β is unclear. In
the current study, we first mapped the critical region for
CBF-β binding at the C-terminus of HIV-1 Vif by using
the NL4-3 strain Vif sequence (Vif) to create C-terminal
truncated mutants of various lengths and found that the
Vif 1-141 truncated mutant, but not Vif 1-124, Vif 1-109
or Vif 1-91 truncated mutant, still maintained a certain
degree of binding to CBF-β. These results showed that
certain amino acids between positions 141 and 124 are
required for the CBF-β interaction. Subsequently, we
screened a series of single-site Vif mutants in this region.
Our results suggested that the mutations Y135A, G138A,
G126A and E134A in this region affect the suppressive
function of Vif on A3G/A3F antiviral activity, which is
due to loss of the ability to interact with CBF-β. More-
over, the data also indicated that the HCCH motif itself
affects the binding with CBF-β. Thus, we have identi-
fied several amino acids at the C-terminus of HIV-1 Vif
that are important for the interaction with CBF-β andVif function, which may be novel targets for the devel-
opment of HIV-1 inhibitors.
Methods
Plasmid construction
The Vif mutant infectious molecular clone (pNL4-3ΔVif)
was obtained from the AIDS Research Reagents Program,
Division of AIDS, National Institute of Allergy and Infec-
tious Diseases, National Institutes of Health (NIH-ARRRP).
The VR1012 vector was generously provided by Vical. Vif-
HA was constructed by PCR amplifying codon optimized
Vif from NL4-3 (residues 1-192) with a C-terminal HA
tag and cloning the product into VR1012 via EcoRI and




(HA). All truncated Vif mutants (1-176, 1-150, 1-141,
1-91, 1-109, 1-124) were amplified from the WT Vif-HA
plasmid and inserted into VR1012 via EcoRI and BamHI
sites. Plasmids for HIV-1 Vif mutants H108A, C114A,
L125A, G126A, R127A, I128A, V129A, S130A, P131A,
R132A, C133A, E134A, Y135A, Q136A, A137S, G138A,
H139A, N140A and K141A also were constructed from
the WT Vif plasmid by site-directed mutagenesis. Plas-
mids for SIVmac Vif mutants C116S, C135S and C116/
135S were derived from the SIVmac Vif-HA plasmid by
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expressing vector pcDNA3-A3F-V5 was a kind gift from
Yonghui Zheng and B. Matija Peterlin at the University of
California, San Francisco [3]. The expression vectors
pc-hA3G-HA, pc-hA3G-V5, SIVtan Vif-HA, SIVtan Vif
SLQ-AAA, H111L, C117S, C135S, H141L and SIVmac
Vif-HA were described previously [14,22].
Cell culture, transfection and antibodies
The human HEK293T (ATCC, catalog no. CRL-11268)
and MAGI (NIH-ARRRP, catalog no. 3522) cells from Julie
Overbaugh [53] were maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen) with 10% fetal
bovine serum and penicillin/streptomycin (D-10 medium)
and passaged upon confluence. DNA transfection with
PEI reagent was carried out according to the manufac-
turer’s instructions (Polyscience, catalog no. 23966-2). The
following antibodies or antisera were used in this study:
anti-CUL5 (H-300) rabbit polyclonal antibody (Santa Cruz
Biotechnology, sc-13014), anti-Vif rabbit polyclonal anti-
body (NIH-ARRRP, catalog no 2221), CAp24 monoclonal
antibody (NIH-ARRRP, catalog no. 1513), anti-HA rabbit
polyclonal antibody (Santa Cruz Biotechnology, 71-5500),
anti-CBF-β monoclonal antibody (Santa Cruz Biotechnol-
ogy, sc-166142), anti-ElonginB (FL-118) rabbit polyclonal
antibody (Santa Cruz Biotechnology, sc-1144), anti-V5
monoclonal antibody (Invitrogen, R960-25), anti-β-
tubulin monoclonal antibody (Tianjin Sanjian, catalog
no. DKM9003). MG132 was purchased from Sigma
(catalog no. C2211).
Virus purification, viral infectivity (MAGI) assay and A3G/
A3F degradation
For APOBEC3 (A3G or A3F) degradation and APOBEC3
proteins packaging assays, HEK293T cells were transfected
with 0.5 μg of NL4-3ΔVif, 0.1 μg of negative control vec-
tor VR1012 or WT or mutant Vif and 0.5 μg of A3G-HA
or A3F-HA in six-well plates. Viruses were produced by
transfecting HEK293T cells and harvesting the super-
natant, while the cells were reserved for detection of A3G
or A3F degradation. Viruses in cell culture supernatants
were cleared of cellular debris by centrifugation and filtra-
tion through a 0.22-μm-pore size membrane (Millipore).
Virus particles were then concentrated by ultracentrifu-
gation. Viral pellets were resuspended in lysis buffer
(PBS containing 1% Triton X-100 and Complete protease
inhibitor cocktail [Roche]). Viral lysates were analyzed by
Western blotting.
Viral infectivity was determined by the MAGI assay as
follows [53]. MAGI cells were prepared in 24-well plates
in D-10 medium 1 day before infection. Cells at 30–40%
confluency on the day of infection were infected by
removing the medium from each well and adding dilu-
tions of virus in a total volume of 500 μl of completeDMEM with 20 μg of DEAE-dextran per well. After 2 h
of incubation at 37°C in a 5% CO2 incubator, 500 μl of
complete DMEM was added to each well, and the cells
were incubated for 48 h under the same conditions. The
supernatants were removed, and 500 μl of fixing solution
(1% formaldehyde, 0.2% glutaraldehyde in PBS) was added.
After 5 min of incubation, the cells were washed twice with
PBS. The staining solution (20 μl of 0.2 M potassium ferro-
cyanide, 20 μl of 0.2 M potassium ferricyanide, 2 μl of 1 M
MgCl2 and 10 μl of 40 mg/ml 5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside [X-Gal]) was added. Cells were incu-
bated for 2 h at 37°C in a non-CO2 incubator. Staining was
stopped by removing the staining solution, and the cells
were thoroughly washed twice with PBS. β-galatosidase
activity is under the control of the HIV-1 LTR promoter,
which is trans-activated in this system. Positive blue dots,
which indicate the presence of integrated virus, were
counted, and viral infectivity was determined after normal-
izing the amount of input virus to the p24 antigen content.
All results represent infections performed in triplicate.
Immunoprecipitation and Western blot analysis
To assess the binding of Vif mutants to CBF-β and other
factors in the CUL5 E3 ligase complex, HEK293T cells
were transfected with 1 μg of WT or mutant Vif expression
vectors in six-well plates. To test the interaction between
Vif and A3G or A3F, the ratio of Vif to A3G or A3F was
1:3 (0.5 μg and 1.5 μg), and MG132 was added to the cells
at the final concentration of 10 μM 12 h before harvest.
Harvested cells were re-suspended in lysis buffer [50 mM
Tris-HCL (pH 7.5),150 mM NaCl, 0.5% (v/v) NP-40 and
Complete protease inhibitor cocktail tablets] and incubated
at 4°C for 30 min, followed by centrifugation at 13,000 rpm
for 30 min. For HA-tag immunoprecipitation, pre-cleared
cell lysates were mixed with anti-HA antibody-conjugated
agarose beads (Roche) and incubated at 4°C for 3 h. Sam-
ples were then washed six times with washing buffer
[20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.1 mM EDTA,
0.05% (v/v) Tween-20]. Proteins binding to the beads were
eluted with elution buffer (0.1 mM glycine-HCl, pH 2.0) or
4× loading buffer. The eluted materials were subsequently
analyzed by Western blot.
Results
A novel region in HCCH motif of HIV-1 Vif is required for
maintaining Vif-CBF-β interaction
Some N-terminal amino acids in HIV-1 Vif have been
shown to be important for the interaction with CBF-β
[22,24,50-52]. In order to determine whether the C-
terminus of Vif is critical for CBF-β binding, we con-
structed a series of expression vectors containing various
C-terminal truncated NL4-3 Vif sequences with a HA tag
at the C-terminus (Figure 1A). We transfected HEK293T
cells with the negative control vector VR1012, wild-type
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Figure 1B. At 48 h after transfection, cells were harvested,
lysed and then loaded onto HA agarose-conjugated beads
for immunoprecipitation. The WT and truncated Vif 1-176
mutant proteins were efficiently co-immunoprecipitated
with ELOB/C, CBF-β and CUL5 (Figure 1B, lanes 2, 3 and
8). These factors were not co-immunoprecipitated in the
absence of Vif, indicating the specificity of the assay
(Figure 1B, lanes 1 and 7). Vif 1-150 and Vif 1-141 all lost
the ability to interact with ELOB/C and CUL5, but they
could still bind to CBF-β with a subtle decrease in reactivity
compared to the WT Vif (Figure 1B, lanes 4 and 5). How-
ever, Vif 1-91, Vif 1-109 and Vif 1-124 lost the ability to
interact with ELOB/C, CUL5 and CBF-β (Figure 1B, lanes
6, 9 and 10). Thus, Vif truncated mutants that retained the
whole HCCH domain (i.e., Vif 1-176, Vif 1-150 and Vif 1-
141) kept some degree of interaction with CBF-β, but those
that had an impaired HCCH domain (i.e., Vif 1-124, Vif 1-
109, Vif 1-91) all lost the interaction with CBF-β.
Taken together, these data showed that Vif truncated
mutants lacking the BC box and containing the HCCH
motif still maintained the ability to interact with CBF-β,
but those that had a disrupted HCCH region lost the
ability to interact with CBF-β. Therefore, we speculated
that certain amino acids in the HCCH region are required
for the Vif-CBF-β interaction.
We further examined the effects of WT and truncated
Vif mutants on A3G degradation, A3G incorporation
into virions and viral infectivity. HEK293T cells were
co-transfected with the Vif mutant infectious molecularFigure 2 Certain residues in HCCH region of Vif are important for intera
(B). Amino acids 124-141 located in HCCH region of Vif involved in CBF-β/CU
vector or WT or various Vif mutants as indicated. Cells were harvested 48 h la
antibody conjugated to agarose beads. Co-precipitated proteins were analyze
binding capacity of WT Vif (100%) and Vif mutants to CBF-β or CUL5. Error baclone NL4-3ΔVif and A3G expression vector along with
VR1012 as a negative control vector or expression vector
for WT or different truncated Vif proteins as indicated in
Figure 1. The intracellular level of A3G was efficiently
reduced by WT Vif (Figure 1C, lane 2) when compared to
the vector control (Figure 1C, lane 1). Except Vif 1-176,
other Vif truncated mutants had an impaired ability to
reduce the expression of A3G (Figure 1C, lanes 4–8).
Accordingly, these Vif truncated mutants had a reduced
ability to exclude A3G from virions and to suppress the
antiviral activity of A3G when compared with WT Vif
(Figure 1C, lanes 4–8 and 1D). These data suggested that
Vif truncated mutants lacking the BC box or having a dis-
rupted HCCH region lost the ability to counteract A3G.
Specific amino acids in HCCH motif of HIV-1 Vif mediate
Vif-CBF-β interaction
As shown above, Vif 1-141 bound to CBF-β with reduced
binding affinity when compared to WT Vif, while Vif 1-
124 completely lost its interaction with CBF-β, suggesting
that certain residues from amino acids 125–141 are
required for Vif binding to CBF-β. We thus generated a
series of Vif mutant constructs in which individual amino
acid residues were replaced with alanine or serine in this
region (Figure 2A). HEK293T cells were transfected with
VR1012 as a negative control vector or WT or various Vif
mutants as indicated in Figure 2B. Interactions of the WT
or Vif mutants with endogenous CUL5, ELOB and CBF-β
were examined by co-immunoprecipitation. As previ-
ously shown [22], CUL5, ELOB and CBF-β were readilyction with CBF-β and/or CUL5. (A) Illustration of Vif mutant constructs.
L5 interaction. HEK293T cells were transfected with VR1012 as a control
ter and subjected to immunoprecipitation analysis using the anti-HA
d by Western blotting against Vif-HA, CUL5, CBF-β and ELoB. (C) Relative
rs represent the standard deviation from triplicate experiments.
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(Figure 2B, lanes 2, 8, 13, 17 and 23).
We found Vif mutants G126A, E134A and G138A were
defective at different levels in binding to CBF-β (Figure 2B,
lanes 4, 15 and 21), and Y135A completely failed to inter-
act with CBF-β (Figure 2C, lane 18). Accordingly, these
mutants exhibited a marked decrease in CUL5 interaction.
These results are consistent with previous reports demon-
strating that CBF-β regulates the Vif-CUL5 interaction
[20-24,48,49]. Unlike with the G126A, E134A, Y135A and
G138A mutants, Vif L125A showed an impaired inter-
action with CUL5 but not CBF-β (Figure 2B lanes 3),
while the R127A mutant was defective in binding to both
CUL5 and CBF-β, with a stronger effect observed on
the Vif-CUL5 interaction than the Vif-CBF-β interaction
(Figure 2B lanes 5). Thus, L125 and R127 may mainly regu-
late CUL5 binding, consistent with the published crystal
structure of Vif-CBF-β-ELOB/C-CUL5 [54] showing direct
interactions of Vif L125 and R127 with CBF-β. In repeated
experiments in the current study, the G126A, E134A,
Y135A and G138A mutants showed 40–90% reduction in
binding to CBF-β and CUL5 when compared with WT Vif;
meanwhile, L125A and R127A showed 80–90% reduction
in CUL5 binding and 0–30% reduction in CBF-β binding
(Figure 2C). The findings here are consistent with our pre-
vious observation that CUL5 silencing did not affect the
Vif-CBF-β interaction, while CBF-β silencing affected the
binding of Vif to CUL5 [22]. Thus, the identification of the
importance of HIV-1 Vif G126, E134, Y135 and G138 in
CBF-β binding further confirmed that the region from
amino acid 125–141 at the C-terminus of HIV-1 Vif is
required for the Vif-CBF-β interaction.
HCCH motif in HIV-1 Vif affects Vif-CBF-β interaction
After determining above that certain residues in the
HCCH region affected the Vif-CBF-β interaction, we
wondered whether the entire HCCH motif which is
known to affect the Vif-CUL5 interaction would also
influence the Vif-CBF-β interaction. This hypothesis was
investigated by transfecting HEK293T cells with VR1012
as a negative control vector or expression vectors for
WT Vif or various Vif mutants as indicated in Figure 3A.
As expected, the H108A, C114A, C133A and H139A
mutants could not interact with CUL5 (Figure 3A, lanes
3, 4, 5 and 6). Moreover, the H108A, C114A, C133A and
H139A mutants also showed a decreased interaction
with CBF-β, suggesting that these residues, which were
previously shown to stabilize the conformation of the Vif
α-domain [54], not only affect the interaction with
CUL5 but also contribute to Vif binding with CBF-β.
We next detected whether the SLQ-AAA mutation,
which affects the Vif-ELOB/C interaction [30], has an
influence on Vif binding with CBF-β. The results
showed that the SLQ-AAA mutant completely lost theability to interact with CBF-β (Figure 3A, lane 9) when
compared with WT Vif (Figure 3A, lane 8). Primate
lentivirus Vif proteins have been shown to all require
CBF-β to degrade their host restriction factors. In order
to determine whether SLQ-AAA and the HCCH motif
in SIVtan and SIVmac Vif proteins have a similar effect
on the interaction between Vif and CBF-β, we transfected
VR1012 as a negative control or expression vectors for
WT SIVtan Vif or various SIVtan Vif mutants into
HEK293T cells in six-well plates. Similar to the HCCH
motif in HIV-1 Vif, the HCCH motif in SIVtan Vif
(Figure 3B, lanes 4, 5, 6 and 7) also showed a very weak
interaction with CBF-β compared with WT SIVtan Vif
(Figure 3B, lane 2). SIVmac Vif also showed similar results
to those of HIV-1 and SIVtan Vifs. These results indicated
that the HCCH motif in primate lentivirus Vif proteins
also contribute to binding with CBF-β.
Certain residues in HCCH motif of HIV-1 Vif are required
for suppression of A3G and A3F
After identifying the CBF-β binding residues in the Vif
HCCH region, we further analyzed the effect of these Vif
mutants on the antiviral activity of A3G proteins. The
MAGI assay was used to analyze the function of Vif mu-
tants against A3G (Figure 4). As expected, Vif mutants
L125A, G126A, R127A, C133A, E134A, Y135A, G138A
and H139A were defective in the suppression of A3G anti-
viral activity (Figure 4A). As a control, other Vif mutants,
including I128A, V129A, S130A, P131A, R132A, Q136A,
A137S, N140A and K141A, showed abilities to inhibit
A3G comparable to that of WT Vif. To further confirm
whether these Vif mutations that abolished the A3G
suppression are due to reduced abilities to degrade and
exclude A3G from virons, A3G expression levels in cells
and virions were analyzed (Figure 4B). The Vif mutants
L125A, G126A, R127A, C133A, E134A, Y135A, G138A
and H139A (Figure 4B, lanes 3, 4, 5, 13, 14, 17, 20 and 23)
were found to be defective in degrading A3G and
excluding it from HIV-1 virions compared with WT Vif
(Figure 4B, lanes 2, 8, 16 and 22).
To further confirm whether the identified residues are
also important for Vif suppression of another APOBEC3
protein, we also examined the effects of these mutants
on the antiviral activity and expression of A3F, with empty
vector VR1012 used as a negative control. The Vif mutants
L125A, G126A, R127A, E134A, Y135A and G138A were
confirmed to have reduced inhibitory effects on A3F anti-
viral activity relative to that of WT Vif (Figure 5A). The
intracellular level of A3F also was restored with these
Vif mutants (Figure 5B, lanes 3, 4 5, 8, 9 and 10) when
compared to that with WT Vif (Figure 5B, lanes 2 and 7).
Additionally, higher levels of A3F were found in HIV-1 vi-
rions with Vif mutants (Figure 5B, lanes 3, 4 5, 8, 9 and 10)
compared to that with WT Vif (Figure 5B, lanes 2 and 7).
Figure 3 The HCCH motif in primate lentiviral Vif proteins is involved in CBF-β/CUL5 interactions. HCCH or SLQ-AAA mutants in HIV-1 Vif (A),
SIVtan Vif (B) or SIVmac Vif (C) were transfected into HEK293T cells as indicated. Cells were harvested 48 h later and subjected to immunoprecipitation
analysis using the anti-HA antibody conjugated to agarose beads. Co-precipitated proteins were analyzed by Western blotting against Vif-HA, CUL5,
CBF-β and ELOB.
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CBF-β or CUL5 do not influence its interaction with A3G
or A3F
We have shown that some mutations in the HCCH
region of HIV-1 Vif affect their function and the Vif-
CBF-β or Vif-CUL5 interaction. In order to determine
whether these mutations induced conformational changes
that abolished the interaction of Vif with CBF-β or
CUL5, we further examined the ability of Vif mutants
to bind target protein A3G or A3F. HEK293T cells
were transfected with negative control vector VR1012
or WT or different Vif mutants plus A3G-V5 or A3F-V5. Cells were treated with 10 μM MG132 12 h prior
to harvesting. At 48 h after transfection, cells were
harvested, lysed and then loaded onto HA agarose-
conjugated beads for immunoprecipitation. All Vif
mutants were efficiently co-immunoprecipitated with
A3G or A3F similar to results with WT Vif (Figure 6A
and B, lanes 2–8). These interactions were specific,
since A3G-V5 or A3F-V5 was not detected in the
absence of Vif (Figure 6A and B, lane 1). These results
suggested that these Vif mutants were not misfolded
and the altered amino acids resulted in loss of their
interaction with CBF-β or CUL5.
Figure 4 Effects of Vif mutations in the region from amino acid 124-141 on the antiviral activity of A3G. (A) Effects of WT and mutant
Vif proteins on A3G antiviral activity. HIV-1 viruses were produced by transfecting HEK293T cells with NL4-3ΔVif and A3G along with VR1012 as a
control vector or WT or various Vif mutants as indicated. Virus infectivity was assessed using MAGI indicator cells, with the virus infectivity in the
presence of WT Vif set to 100%. Error bars represent the standard deviation from triplicate wells. (B) Effects of WT and mutant Vif proteins on A3G
degradation and virion packaging. A3G expression was assessed by Western blotting against A3G-HA, Vif-HA and tubulin as loading control. A3G
packaging was evaluated by Western blotting against A3G-HA and CAp24 after virus was purified from the cell culture supernatant.
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In the current study, we determined that certain residues
in the C-terminus of HIV-1 Vif play an important role
for binding with CBF-β by detecting the interaction
between C-terminal truncated Vif mutants of various
lengths with CBF-β. The truncated Vif mutants tested
showed binding affinities at different degrees for CBF-β.
Compared to WT, Vif 1-176 and Vif 1-150 maintained
the WT level of binding with CBF-β, suggesting that the
C-terminal region (amino acids 151–192) of Vif is not
essential for this interaction. However, Vif 1-141 had a
slightly reduced interaction with CBF-β, meanwhile, Vif
1-124 poorly bound to CBF-β, and Vif 1-109 completely
lost the ability to interact with CBF-β (Figure 1B). Thus,
some residues between positions 125 and 141 located in
the HCCH region of Vif, which have been thought to be
critical for CUL5 binding [36,54], are also involved in
CBF-β binding. Interestingly, our findings are consistent
with a previous study which reported that Vif 1-140
retains the WT binding capacity to CBF-β in vitro [23].
However, our results are different from those of another
study proposing that Vif 1-109 still retains the ability to
bind CBF-β but with a reduced affinity by using a co-expression and co-purification system in Escherichia coli
[50]. As over-expression of proteins in vitro increases
their chance of interacting with each other, we speculate
that a small fraction of Vif 1-109 and CBF-β survived
the purification due to the great abundance of expressed
proteins.
Notably, the Vif 1-141 truncated mutant missing the
BC box still bound to CBF-β, although with minimally
reduced binding affinity in vivo (Figure 1B). By contrast,
the SLQ-AAA mutant totally lost the ability to interact
with CBF-β, similar to the result obtained when silen-
cing ELOB (Figure 3) [55]. Others have speculated that
Vif binds ELOB/C at its C-terminus followed by CBF-β
at its N-terminus, inducing structural changes at both
termini. Once Vif is bound to both CBF-β and ELOB/C,
CUL5 binds to Vif, requiring residues in both the N-
and C-terminus of the protein to assemble a functional
ubiquitin ligase [56]. Therefore, the processes of Vif
binding to ELOB/C and to CBF-β are closely associated.
We deduced that the truncation of the Vif 1-141 mutant
may have exposed the binding sites for CBF-β or facili-
tated the CBF-β interaction. This observation is also
consistent with a previous determination that CBF-β
Figure 5 Effects of Vif mutations in the region from amino acid 124-141 on the antiviral activity of A3F. (A) Effects of WT and mutant
Vif proteins on A3F antiviral activity. HIV-1 viruses were produced by transfecting HEK293T cells with NL4-3ΔVif and A3F along with VR1012 as a
control vector or WT or various Vif mutants as indicated. Virus infectivity was assessed using MAGI indicator cells, with the virus infectivity in the
presence of WT Vif set to 100%. Error bars represent the standard deviation from triplicate wells. (B) Effects of WT and mutant Vif proteins on A3F
degradation and virion packaging. A3F expression was assessed by Western blotting against A3F-V5, Vif-HA and tubulin as loading control. A3F
packaging was evaluated by Western blotting against A3F-V5 and CAp24 after virus was purified from the cell culture supernatant.
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even without co-expression with ELOB/C [23].
We further identified several residues in the HCCH
region of HIV-1 Vif that when mutated affected Vif-
mediated A3G and A3F degradation/suppression by
disrupting its interaction with CBF-β. Alanine or serine
substitution mutants showed that amino acids G126,
E134, Y135 and G138 in the Vif 124-141 region (Figure 2)
clearly reduced/abolished the CBF-β interaction. Although
these residues do not come into contact with CBF-β
directly based on the crystal structure [54], they may be
required for the conformation of Vif to facilitate CBF-β
binding. Mutations of these residues impaired the ability
of Vif to suppress A3G/A3F (Figures 4 and 5). However,
these Vif mutants did not lose their interaction with
ELOB (Figure 2), A3G or A3F (Figure 6), suggesting
their conformational changes at least had no effect on
the interaction with ELOB and the substrate. Thus,
besides an extensive region of the Vif N-terminus, in-
cluding dispersed and conserved hydrophobic aminoacids that were shown previously to bind to CBF-β
[22,24,50-52], the finding of C-terminal residues in Vif
that also are involved in CBF-β binding further clarified the
interaction pattern of Vif-CBF-β. As both the N-terminal
and C-terminal domains of Vif function in CBF-β binding,
the simultaneous use of additional domains or a specific
conformational shape to bind CBF-β and facilitate assembly
of the Vif-CUL5 E3 ligase would seem to be required.
Previous studies have established that the HIV-1 Vif
HCCH motif is required for binding with CUL5 [33-39].
The zinc-finger motif may stabilize the conformation of
the α–domain to promote Vif interaction with CUL5
[50,54]. Mutations of two equivalent HIV-1 Vif residues
in HXB2 Vif, I120S and L124S [35], or other key residues
have been shown to impair Vif interaction with CUL5.
Finding that the HCCH domain may also contribute the
interaction of Vif with CBF-β was surprising (Figure 3).
Thus, we speculate that the conformational shape of Vif is
also required for the CBF-β interaction, which then facili-
tates CUL5 binding and the assembly of Vif-CUL5 E3
Figure 6 Unaltered interactions of Vif mutants with A3G or A3F imply no changes in conformation from WT Vif protein HEK293T cells
were transfected with the vector control or WT or Vif mutant plus A3G-V5 (A) or A3F-V5 (B). Cells were treated with 10 μM MG132 12 h
prior to harvesting, and then Vif-HA was immunoprecipitated from cell lysates with the anti-HA antibody conjugated to agarose beads. The interaction
of Vif-HA with A3G-V5 or A3F-V5 was detected by Western blotting against Vif-HA and A3G-V5 or A3F-V5.
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in CBF-β binding and CUL5 binding.
Until now, we have found that most of the residues
that affect the interaction with CUL5 also affect the
interaction with CBF-β. Therefore, a specific conform-
ation of Vif may be important for its interactions with
CUL5 and even more importantly with CBF-β, which is
consistent with data showing that silencing of CBF-β
inhibits the interaction between Vif and CUL5 [22]. How-
ever, unlike most of the CUL5 binding sites identified
previously, here we observed that Vif L125A only affected
CUL5 binding but maintained the WT levels of binding to
ELOB and CBF-β.
As a substrate receptor, Vif not only recruits ELOB/C,
RBX and CBF-β to form an E3 ubiquitin ligase, it also
needs to recognize different APOBEC3 proteins for deg-
radation. Different functional domains of Vif have been
well characterized. Vif proteins of different HIV-1 subtypesand SIV have all been determined to require CBF-β to
degrade A3G [22,48], and the current study further delin-
eates the role of various Vif regions. Identification of G126,
E134, Y135 and G138 of HIV-1 Vif in the Vif-CBF-β inter-
action better defines the Vif functional domain, which may
be help to facilitate the development of novel therapeutic
strategies for HIV-1 infection.
Conclusions
Certain amino acids (G126A, E134A, Y135A and G138A)
in the C-terminus of HIV-1 Vif were identified as binding
sites for the interaction with CBF-β. The HCCH motif
itself, which is required for CUL5 interaction, also affects
Vif-CBF-β interaction. Furthermore, we speculate that
binding to ELOB/C induces conformational changes in
Vif, facilitating its interaction with CBF-β and consequent
interaction with CUL5. The results provide important in-
formation on the assembly of the Vif-CUL5-E3 ubiquitin
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CBF-β at the C-terminus of HIV-1 Vif also provides novel
targets for the development of HIV-1 inhibitors.
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